How much does a box of Fam-trastuzumab deruxtecan-nxki cost?

Fam-trastuzumab deruxtecan-nxki is approved to treat breast cancer in adults that cannot be removed with surgery or has spread to other parts of the body. It is used in patients with metastatic cancer who have HER2-positive cancer and have received anti-HER2 therapy, or in patients whose cancer has come back during or within 6 months of completing anti-HER2 therapy for earlier cancer. Also in patients withher2-low-level cancer who have received chemotherapy for metastatic cancer or whose cancer relapses during or within 6 months of chemotherapy given after completing surgery.

Trastuzumab is used for HER2-positive gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer) that has spread in adults who are receiving treatments including trastuzumab. Trastuzumab is also used in patients who have received systemic therapy and have non-small cell lung cancer that has a certain mutation in the HER2 gene that cannot be removed by surgery or has spread to other parts of the body. The use of trastuzumab is approved under the accelerated approval program of the U.S. Food and Drug Administration (FDA). As a condition of approval, confirmatory trials must show that trastuzumab has clinical benefit in these patients.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of TrastuzumabSpecifications100mg may cost more than 10,000 yuan per box, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to exchange rate effects). The drug ingredients of the two are basically the same. There is currently no generic drug of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.